Apoptosis in membranous bone formation: Role of fibroblast growth factor and bone morphogenetic protein signaling

Critical Reviews in Eukaryotic Gene Expression

Volumn 15, Issue 1, 2005, Pages 75-92

  Fromigué, Olivia ^a   Modrowski, Dominique ^a   Marie, Pierre J ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cranial bone; Differentiation; Osteoblasts; Suture

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C;

APOPTOSIS; BONE MINERALIZATION; CALVARIA; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; HUMAN; HUMAN CELL; MESENCHYME CELL; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUTURE REMOVAL; UPREGULATION;

APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CRANIAL SUTURES; FIBROBLAST GROWTH FACTORS; OSTEOBLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 18944395924     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v15.i1.50     Document Type: Review

References (157)

1. Couly GF, Coltey PM, Le Douarin NM. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. Development 11993; 17(2):409-29.
2. Opperman LA. Cranial sutures as intramembranous bone growth sites. 2000; Dev Dyn 219:472-485
3. Hall BK, Miyake T. All for one and one for all: condensations and the initiation of skeletal development. Bioessays 2000; 22(2):138-147.
4. Cohen MM. Transforming growth factor beta and fibroblast growth factors and their receptors: role in suturai biology and craniosynostosis. J Bone Miner Res 1997; 12:322-330.
5. Most D, Levine JP, Chang J, Sung J, McCarthy JG, Schendel SA, Longaker MT. Studies in cranial suture biology: up-regulation of transforming growth factor-β1 and basic fibroblast growth factor mRNA correlates with posterior frontal cranial suture fusion in the rat. Plast Reconstr Surg 1998; 101:1431-1440.
6. Rice D, Kim H, Thesleff I. Apoptosis in murine calvarial bone and suture development. Eur J Oral Sci 1999; 107:265-275.
7. Morris-Kay GM, Iseki S, Johnson D. Genetic control of the cell proliferation-differentiatiOn balance in the developing skull vault: roles of fibroblast growth factor receptor signalling pathways. Novartis Found Symp 2001; 232:102-116.
8. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996; 76(2):593-629.
9. Marie PJ. Osteoblasts and bone formation. In: Zaidi L, editor. Advances in organ biology: molecular and cellular biology of bone. Vol. 5B. London: JAI Press; 1998. p. 445-473.
10. Aubin, JE. Mesenchymal stem cells and osteoblast differentiation. In Bilezikian J, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 2002. p. 59-82.
11. Banerjee C, McCabe LR, Choi JY, Hiebert SW, Stein JL, Stein GS, Lian JB. Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem 1997; 66(1):1-8.
12. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89, 747-754.
13. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 30;89(5):755-64.
14. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89, 773-779.
15. Liu YH, Kundu R, Wu L, Luo W, Ignelzi MA Jr, Snead MT., Maxson RE Jr. Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc Natl Acad Sci U S A 1995; 92(13):6137-6141.
16. Liu YH, Tang Z, Kundu RK, Wu L, Luo W, Zhu D, Sangiorgi F, Snead ML, Maxson RE. Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: a possible mechanism for MSX2-mediated craniosynostosis in humans. Dev Biol 1999; 205(2):260-74.
17. Jabs EW, Muller U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Mulliken JB. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75, 443-450.
18. Ignelzi MA Jr, Wang W, Young AT. Fibroblast growth factors lead to increased Msx2 expression and fusion in calvarial sutures. J Bone Miner Res 2003; 18(4):751-759.
19. Dodig M, Tadic T, Kronenberg MS, Dacic S, Liu YH, Maxson R, Rowe DW, Lichtler AC. Ectopic Msx2 overexpression inhibits and Msx2 antisense stimulates calvarial osteoblast differentiation. Dev Biol 1999; 209(2):298-307.
20. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 2000; 24(4):391-395.
21. Wilkie AO, Tang Z, Elanko N, Walsh S, Twigg SR, Hurst JA, Wall SA, Chrzanowska KH, Maxson RE Jr. Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nat Genet 2000; 24, 387-390.
22. Acampora D, Merlo GR, Paleari L, Zerega B, Postiglione MP, Mantero S, Bober E, Barbieri O, Simeone A, Levi G. 1Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5. Development 999; 126(17):3795-3809.
23. Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. Genes Cells 2001; 6(10):851-856.
24. Ryoo HM, Hoffmann HM, Beumer T, Frenkel B, Towler DA, Stein GS, Stein JL, van Wijnen AJ, Lian JB. Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol 1997; 11(11):1681-1694.
25. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Invest 2001; 107(9):1153-1161.
26. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, Justice MJ, Karsenty G. A twist code determines the onset of osteoblast differentiation. Dev Cell 2004; 6(3):423-435.
27. Yousfi M, Lasmoles F, El Ghouzzi V, Marie PJ. TWIST haploinsufficiency in the Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFα expression and caspase-2 activation. Hum Mol Genet 2002; 11:4359-4369.
28. Yousfi M, Lasmoles F, Marie PJ. TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts. Biochem Biophys Res Commun 2002; 297(3):641-644.
29. Erratum in Biochem Biophys Res Commun 2003; 305(1):209.
30. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997; 15(1):42-46.
31. Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI, Garcia Delgado C, Gonzalez-Ramos M, Kline AD, Jabs EW. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997; 15(1):36-41.
32. Stankiewicz P, Thiele H, Baldermann C, Kruger A, Giannakudis I, Dorr S, Werner N, Kunz J, Rappold GA, Hansmann I. Phenotypic findings due to trisomy 7p15.3-pter including the TWIST locus. Am J Med Genet 2001; 103(1):56-62.
33. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21(2):115-37.
34. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005; 328(3):709-20.
35. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002; 16(12):1446-1465.
36. Jilka JR, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998; 13:793-802.
37. Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 1997; 138, 3849-3858.
38. Ten Gate AR, Freeman E, Dickinson JB. Sutural development: structure and its response to rapid expansion. Am J Orthod 1977; 71(6):622-636.
39. Furtwangler JA, Hall SH, Koskinen-Moffett LK. Sutural morphogenesis in the mouse calvaria: the role of apoptosis. Acta Anat (Basel) 1985; 124:74-80.
40. Bourez RL, Mathijssen IM, Vaandrager JM, Vermeij-Keers C. Apoptotic cell death during normal embryogenesis of the coronal suture: early detection of apoptosis in mice using annexin V. J Craniofac Surg 1997; 8:441-445.
41. Kumar S, Harvey NL. Role of multiple cellular proteases in the execution of programmed cell death. FEES Lett 1995; 375:169-73.
42. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
43. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308.
44. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 2000; 256:19-26.
45. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Koji T, Urayama S, Fujiyama K, Kiriyama T, Nakashima T, Nakane PK, Nagataki S. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 1997; 12:1637-1646.
46. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, Fujiyama K, Kiriyama T, Aoyagi T, Maeda K, Eguchi K. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts.1999; J Lab Clin Med 134:222-231.
47. Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D. Osteoblast apoptosis and bone turnover. J Bone Miner Res 2001; 16(6):975-984.
48. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88(4):435-437.
49. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11:701-713.
50. Golden LH, Insogna KL. The expanding role of PI3-kinase in bone. Bone 2004; 34, 3-12.
51. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T. 2004; Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 166(1):85-95.
52. Akeno N, Robins J, Zhang M, Czyzyk-Krzeska MF, Clemens TL. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 2002; 143(2):420-425.
53. Danciu TE, Adam RM, Naruse K, Freeman MR, Hauschka PV. Calcium regulates the PI3K-Akt pathway in stretched osteoblasts. FEBS Lett 2003; 536(1-3):193-197.
54. Borgatti P, Martelli AM, Bellacosa A, Casto R, Massari L, Capitani S, Neri LM. Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Lett 2000; 477(1-2):27-32.
55. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998; 8:55-62.
56. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998; 273(32):19929-19932.
57. Dominguez I, Green JB. Missing links in GSK3 regulation. Dev Biol 2001; 235(2):303-313.
58. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406:86-90.
59. Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP-2 mediated signal transduction. Biochem Biophys Res Commun 2003; 301:84-91.
60. Kahler RA, Westendorf JJ. Lymphoid Enhancer Factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem 2003; 278:11937-11944.
61. Tanaka Y, Nakayamada S, Fujimoto H, Okada Y, Umehara H, Kataoka T, Minami Y. H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. J Biol Chem 2002; 277(24):21446-21452.
62. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor kinases: molecular analysis and signal transduction. Biochem Biophys Acta 1992; 1135:185-199.
63. Hurley MM, Marie PJ, Florkiewicz RZ. Fibroblast growth factor (FGF) and FGF receptor families in bone. In Bilezikian J, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 2001. p. 825-851.
64. Marie PJ. Fibroblast Growth Factor signaling controlling osteoblast differentiation. Gene 2003; 316:23-32.
65. Gonzalez AM, Hill DJ, Logan A, Maher PA, Baird A. Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus. Pediatr Res 1996; 39(3):375-385.
66. Rice DP, Rice R, Thesleff I. Fgfr mRNA isoforms in craniofacial bone development. Bone 2003; 33(1):14-27.
67. Britto JA, Chan JC, Evans RD, Hayward RD, Jones BM. Differential expression of fibroblast growth factor receptors in human digital development suggests common pathogenesis in complex acrosyndactyly and craniosynostosis. Plast Reconstr Surg 2001; 107(6):1331-1338.
68. Kim H-J, Rice DPC, Kettunen PJ, Thesleff I. FGF-, BMP- and Shh-mediated signaling pathways in the regulation of cranial suture morphogenesis and calvaria bone development. Development 1998; 125:1241-1251
69. Hajihosseini MK, Heath JK. Expression patterns of fibroblast growth factors-18 and -20 in mouse embryos is suggestive of novel roles in calvarial and limb development. Mech Dev 2002; 113(1):79-83.
70. Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, Takada S. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 2002; 16(7):870-879.
71. Givol D, Yahon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992; 6:3362-3369.
72. Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Le Merrer M, Munnich A, Vekemans M, Bonaventure J. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev 1998; 77(1):19-30.
73. Molténi A, Modrowski D, Hott M, Marie PJ. Differential expression of fibroblast growth factor receptor-1, -2, and -3 and syndecan-1, -2, and -4 in neonatal rat mandibular condyle and calvaria during osteogenic diffentiation in vitro. Bone 1999; 24(4):337-347.
74. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I. Integration of FGF and TWIST in calvarial bone and suture development. Development 2000; 127(9):1845-1855.
75. Iseki S, Wilkie AOM, Heath JK, Ishimura T, Eto K, Morriss-Kay GM. FGFR-2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF-2. Development 1997; 124:3375-3384.
76. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22(2):108-112.
77. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. The IIIC alternative of FGFR-2 is a positive regulator of bone formation. Development 2002; 129(16):3783-3793.
78. Modrowski D, Baslé M, Lomri A, Marie PJ. Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem 2000; 275(13):9178-9185.
79. Molténi A, Modrowski D, Hott M, Marie PJ. Alterations of matrix- and cell-associated proteoglycans inhibit osteogenesis and growth response to FGF-2 in cultured rat mandibular condyle and calvaria. Cell Tissue Res 1999; 295:523-536.
80. Mathijssen IM, van Leeuwen H, Vermeij-Keers C, Vaandrager JM. FGF-4 or FGF-2 administration induces apoptosis, collagen type I expression, and mineralization in the developing coronal suture. J Craniofac Surg 2001; 12(4):399-400.
81. Greenwald JA, Mehrara BJ, Spector JA, Warren SM, Fagenholz PJ, Smith LE, Bouletreau PJ, Crisera FE, Ueno H, Longaker MT. In vivo modulation of FGF biological activity alters cranial suture fate. Am J Pathol 2001; 158(2):441-452.
82. Moore R, Ferretti P, Copp A, Thorogood P. Blocking endogenous FGF-2 activity prevents cranial osteogenesis. Dev Biol 2002; 243(1):99-114.
83. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988; 81:1572-1577.
84. Shimoaka T, Ogasawara T, Yonamine A, Chikazu D, Kawano H, Nakamura K, Itoh N, Kawaguchi H. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor. FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem 2002; 277(9):7493-500.
85. Debiais F, Hott M, Graulet AM, Marie PJ. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Miner Res 1998; 13(4):645-654;
86. Tang KT, Capparelli C, Stein JL, Stein GS, Lian JB, Huber AC, Braverman LE, DeVito WJ. Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes. J Cell Biochem 1996; 61:152-166.
87. Schedlich LJ, Flanagan JL, Crofts LA, Gillies SA, Goldberg D, Morrison NA, Eisman JA. Transcriptional activation of the human osteocalcin gene by basic fibroblast growth factor. J Bone Miner Res 1994; 9:143-152.
88. Boudreaux JM, Towler DA. Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. J Biol Chem 1996; 271:7508-7515.
89. Newberry EP, Boudreaux JM, Towler, DA. The rat osteocalcin fibroblast growth factor (FGF-)-responsive element: an okadaic acid-sensitive, FGF-selective transcriptional response motif. Mol Endocrinol 1996; 10:1029-1040.
90. Iseki S, Wilkie AOM, Morris-Kay GM. FGFR-1 and FGFR-2 have distinct differentiation-and proliferation-related roles in the developing mouse skull vault. Development 1999; 126, 5611-5620.
91. Coffin JD, Florkiewicz RZ, Jneumann J, Mort-Hopkins T, Dorn II GW, Lightfoot P, German R, Howles PN, Kier A, O'Toole BA, Sasse J, Gonzalez AM, Baird A, Doetschman T. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell 1995; 6:1861-1873.
92. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 2000; 105(8):1085-1093.
93. Liu Z, Xu J, Colvin JS, Ornitz DM. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 2002; 16(7):859-869.
94. Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX. A Pro250Arg substitution in mouse FGFR-1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 2000; 9(13):2001-2008.
95. Muenke M, Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995; 11:308-313.
96. Wilkie AOM. Craniosynostosis- genes and mechanisms. Hum Mol Genet 1997; 6:1647-1656.
97. Wilkie AO, Morriss-Kay GM. Genetics of craniofacial development and malformation. Nat Rev Genet 2001; 2(6):458-468.
98. Bonaventure J, El Ghouzzi V. Molecular and cellular bases of syndromic craniosynostoses. Exp Rev Mol Med 2003; 5:1-16.
99. Yu K, Herr AB, Waksman G, Ornitz DM. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000; 97:14536-14541.
100. Mansukhani A, Bellosta P, Sahni M, Basilico C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR-2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 2000; 149:1297-1308.
101. Lomri A, Lemonnier J, Hott M, de Perseval N, Lajeunie, E, Munnich A, Renier D, Marie PJ. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor-2 mutations in Apert syndrome. J Clin Invest 1998; 101:1310-1317.
102. Fragale A, Tartaglia M, Bernardini S, Michela Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliacco S. Decreased proliferation and altered differentiation in osteobksts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 1999; 154:1465-1477.
103. Lemonnier J, Hott M, Delannoy P, Lomri A, Modrowski D, Marie PJ. The S252W fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 2000; 256:158-167.
104. Lemonnier J, Hay E, Delannoy P, Lomri A, Modrowski D, Caverzasio J, Marie PJ. Role of N-Cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res 2001; 16(5):832-845.
105. Kim HJ, Kim JH, Bae SC, Choi JY, Kim HJ, Ryoo HM. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 2003; 278(1):319-326.
106. Zhang X, Sobue T, Hurley MM. FGF-2 increases colony formation, PTH receptor, and IGF-1 mRNA in mouse marrow stromal cells. Biochem Biophys Res Commun 2002; 290(1):526-531.
107. Chaudhary LR, Avioli LV. Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: differences in mobility and in-gel renaturation of ERK1 in human, rat, and mouse osteoblastic cells. Biochem Biophys Res Commun 1997; 238(1):134-9.
108. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 2001; 81(1):68-81.
109. Chaudhary LR, Avioli LV. Extracellular-signal regulated kinase signaling pathway mediates down-regulation of type I procoEagen gene expression by FGF-2, PDGF-BB, and okadaic acid in osteoblastic cells. J Cell Biochem 2000; 76(3):354-359.
110. Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem 2002; 277(39):36181-36187.
111. Lomri A, Lemonnier J, Delannoy P, Marie PJ. Identification of genes induced by the Ser252Trp FGFR-2 Apert mutation in osteoblasts using atlas human expression arrays: evidence for increased expression of PKCα, IL-1a and RhoA GTPase. J Bone Miner Res 2001; 16(4):705-712.
112. Bresnick S, Schendel S. Crouzon's disease correlates with low fibroblast growth factor receptor activity in stenosed cranial sutures. J Craniofac Surg 1995; 6:245-250.
113. Kaabeche K, Lemonnier J, Le Mee S, Caverzasio J, Marie PJ. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation. J Biol Chem 2004; 279(35):36259-67.
114. Kelpke SS, Reiff D, Prince CW, Thompson JA. Acidic fibroblast growth factor signaling inhibits peroxynitrite-induced death of osteoblasts and osteoblast precursors. J Bone Miner Res 2001; 16(10):1917-1925.
115. Debiais F, Lefevre G, Lemonnier J, Le Mée S, Lasmoles F, Mascarelli F, Marie PJ. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathway. Exp Cell Res 2004; 297(1):235-246.
116. Lemonnier J, Hay E, Delannoy P, Fromigue O, Lomri A, Modrowski D, Marie PJ. Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C andinterleukin-1. Am J Pathol 2001; 158(5):1833-1842.
117. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. Apoptosis during bone-like tissue development in vitro. J Cell Biochem 1998; 68:31-49.
118. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 1998; 273:13007-13014.
119. Sahni M, Raz R, Coffin JD, Levy D, Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF-2. Development 2001; 128(11):2119-2129.
120. Chaudhary LR, Hruska KA. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem 2001; 81:304-311.
121. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992; 32:160-167.
122. Urist MR. Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res 1997; 12:343-346.
123. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390(6659):465-471.
124. Palcy S, Goltzman D. Protein kinase signalling pathways involved in the up-regulation of the rat alpha1(I) collagen gene by transforming growth factor beta1 and bone morphogenetic protein 2 in osteoblastic cells. Biochem J 1999; 343(Pt 1):21-27.
125. Haÿ E, Lemonnier J, Fromigué O, Marie PJ. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. J Biol Chem 2001; 276(31):29028-29036.
126. Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001; 28(5):491-498.
127. Lai CF, Cheng SL. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 2002; 277(18):15514-15522.
128. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002; 277(7):5330-5338.
129. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003; 18(11):2060-2068.
130. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, Choudhury GG. 2002; Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J Biol Chem 6;277(36):33361-8.
131. Erratum in: J Biol Chem 2003; 278(18):16452.
132. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18(10):1842-1853.
133. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000; 21:393-411.
134. Hay E, Hott M, Graulet AM, Lomri A, Marie PJ. Effects of bone morphogenetic protein-2 on human neonatal calvaria cell differentiation. J Cell Biochem 1999; 72(1):81-93.
135. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003; 24:218-235.
136. Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH. BMP signals regulate Dlx5 during early avian skull development. Dev Biol 2003; 257(1):177-189.
137. Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT. The BMP antagonist noggin regulates cranial suture fusion. Nature 2003; 422 (6932):625-629.
138. Yokouchi Y, Sakiyama J, Kameda T, Iba H, Suzuki A, Ueno N, Kuroiwa A. BMP-2/-4 mediate programmed cell death in chicken limb buds. Development 1996; 122(12):3725-3734.
139. Zou H, Niswander L. Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 1996; 272(5262):738-741.
140. Macias D, Ganan Y, Sampath TK, Piedra ME, Ros MA, Hurle JM. Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development 1997; 124(6):1109-1117.
141. Ferrari D, Lichtler AC, Pan ZZ, Dealy CN, Upholt WB, Kosher RA. Ectopic expression of Msx-2 in posterior limb bud mesoderm impairs limb morphogenesis while inducing BMP-4 expression, inhibiting cell proliferation, and promoting apoptosis. Dev Biol 1998; 197(1):12-24.
142. Guha U, Gomes WA, Kobayashi T, Pestell RG, Kessler JA. In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb. Dev Biol 2002; 249(1):108-120.
143. Merino R, Rodriguez-Leon J, Macias D, Ganan Y, Economides AN, Hurle JM. The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 1999; 126(23):5515-5522.
144. Hay E, Lemonnier J, Fromigué O, Guenou H, Marie PJ. Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells. J Biol Chem 2004; 279(3):1650-1658.
145. Fujii M, Takeda K, Imamura T, Aoki H, Sampath TK, Enomoto S, Kawabata M, Kato M, Ichijo H, Miyazono K. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 999; 10 (11):3801-3813.
146. Mishina Y, Starbuck MW, Gentile MA, Fukuda T, Kasparcova V, Seedor JG, Hanks MC, Amling M, Pinero GJ, Harada S, Behringer RR. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem 2004; 279(26):27560-27566.
147. Chen S, Guttridge DC, Tang E, Shi S, Guan K, Wang CY. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem 2001; 276(42):39259-39263.
148. Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T. BMP-2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 2000; 275(23):17647-17652.
149. Zuzarte-Luis V, Montero JA, Rodriguez-Leon J, Merino R, Rodriguez-Rey JC, Hurle JM. A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev Biol 2004; 272(1):39-52.
150. Marazzi G, Wang Y, Sassoon D. Msx2 is a transcriptional regulator in the BMP4-mediated programmed cell death pathway. Dev Biol 1997; 186:127-138.
151. Grotewold L, Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 2002; 21(5):966-975.
152. Montero JA, Ganan Y, Macias D, Rodriguez-Leon J, Sanz-Ezquerro JJ, Merino R, Chimal-Monroy J, Nieto MA, Hurle JM. Role of FGFs in the control of programmed cell death during limb development. Development 2001; 128(11):2075-84.
153. Canalis E, Gabbitas B. Skeletal growth factors regulate the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures. J Biol Chem 1995; 270(18):10771-10776.
154. Saadeh PB, Mehrara BJ, Steinbrech DS, Spector JA, Greenwald JA, Chin GS, Ueno H, Gittes GK, Longaker MT. Mechanisms of fibroblast growth factor-2 modulation of vascular endothelial growth factor expression by osteoblastic cells. Endocrinology 2000; 141(6):2075-2083.
155. Noda M, Vogel R. Fibroblast growth factor enhances type β1 transforming growth factor gene expression in osteoblast-like cells. J Cell Biol 1989; 109:2529-2535.
156. Johnson D, Iseki S, Wilkie AO, Morriss-Kay GM. Expression patterns of Twist and FGFR-1, -2 and -3 in the developing mouse coronal suture suggest a key role for twist in suture initiation and biogenesis. Mech Dev 2000; 91(1-2):341-5.
157. Funato N, Ohtani K, Ohyama K, Kuroda T, Nakamura M. Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors. Mol Cell Biol 2001; 21(21):7416-7428.